文献速递泌尿生殖腹部MR

整合临床与影像变量的综合评分系统用于双参数MRI检测临床显著性前列腺癌:与多参数MRI的多中心比较

A comprehensive scoring system integrating clinical and radiological variables for the detection of clinically significant prostate cancer on bi-parameter MRI: multi-center comparison with multi-parametric MRI.
PubMed 文献 · Abdom Radiol (NY) · 2025-06-19

这项回顾性多中心研究纳入788例患者,开发并验证了整合%fPSA、S-PI-RADS、aPSA和LD/SD的评分系统,用于活检前预测临床显著性前列腺癌(Gleason分级组≥2)。该评分系统在推导队列和两个验证队列中的AUC分别为0.891、0.875和0.897,与PI-RADS相当(P均>0.05),且在三个队列中阳性预测值最高。按总分分为四类风险组,中位预测概率与观察风险一致,读者间一致性优于PI-RADS。

要点

  • 评分系统整合%fPSA、S-PI-RADS、aPSA和LD/SD,用于活检前预测临床显著性前列腺癌。
  • 评分系统AUC在推导及验证队列为0.891、0.875、0.897,与PI-RADS相当(P均>0.05)。
  • 低危(0-2分)、中低危(3-7分)、中高危(8-12分)、高危(13-17分)组中位预测概率分别为3.8%、14.4%、67.8%、90.3%。

核心结论

  • 该评分系统诊断性能与PI-RADS相当并提高了阳性预测值,突显其潜在临床实用性。

研究设计与样本

  • 回顾性研究,纳入788例患者,按机构分为推导队列和两个验证队列;评估PI-RADS v2.1、S-PI-RADS(结合DWI/ADC上扩散受限程度和病灶体积的定性与定量评估)、前列腺体积、病灶体积及最长/最短径比值。

关键影像表现/征象

  • S-PI-RADS结合DWI/ADC序列上扩散受限程度的定性与定量评估以及病灶体积。
  • 评分系统纳入%fPSA、S-PI-RADS、aPSA和LD/SD四个变量。

诊断标准与关键数值

  • 临床显著性前列腺癌定义为Gleason分级组≥2。
  • aPSA计算公式为tPSA×(LV/PV),%fPSA为游离PSA与总PSA的比值。
  • 评分系统总分0-2分为低危、3-7分为中低危、8-12分为中高危、13-17分为高危。
  • 评分系统AUC在推导队列为0.891、两个验证队列分别为0.875和0.897;PI-RADS相应AUC为0.861、0.880和0.865,所有比较P>0.05。
  • 评分系统在三个队列中阳性预测值分别为0.780、0.832和0.722,为三种系统中最高。

临床应用与阅片要点

  • 低危(0-2分)、中低危(3-7分)、中高危(8-12分)、高危(13-17分)组中位预测概率分别为3.8%、14.4%、67.8%、90.3%,与观察风险一致。
  • PI-RADS在受训与未受训放射科医师之间读者间一致性欠佳(κ=0.643),评分系统一致性更强(κ=0.808)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To develop and validate a scoring system that combines clinical and radiological variables to predict the likelihood of clinically significant prostate cancer (csPCa, which is defined as Gleason Grade group ≥ 2) before biopsy and stratify patients by predicted risk.

METHODS: This retrospective study enrolled 788 patients. Data were stratified into a derivation cohort and two validation cohorts by institutions. Imaging evaluation included: Prostate Imaging Reporting and Data System v2.1 (PI-RADS v2.1), Simplified PI-RADS [S-PI-RADS, incorporating qualitative and quantitative assessment of diffusion restriction degree and lesion volume (LV) on DWI/ADC sequences], prostate volume (PV), LV, and the longest to shortest diameter ratio (LD/SD). %fPSA was the ratio of free prostate-specific antigen (PSA) to total PSA (tPSA). The adjusted PSA (aPSA) was derived as: aPSA = tPSA×(LV/PV). Independent csPCa predictors were determined through multivariate regression analysis and transformed into the scoring system. Diagnostic performance of PI-RADS, S-PI-RADS, and the scoring system were compared using ROC analysis. The scoring system was stratified into four risk categories based on total scores.

RESULTS: The scoring system-integrating %fPSA, S-PI-RADS, aPSA, and LD/SD-demonstrated robust predictive performance for csPCa across all derivation and validation cohorts (AUC: 0.891, 0.875, and 0.897, respectively), comparable to PI-RADS (AUC: 0.861, 0.880, and 0.865; all P > 0.05). It achieved the highest PPV among three systems in all cohorts (0.780, 0.832, and 0.722). Median predicted probabilities for the low (0-2 points), intermediate-low (3-7), intermediate-high (8-12), and high-risk groups (13-17) were 3.8%, 14.4%, 67.8%, and 90.3%, respectively, aligning with observed risks. While inter-reader agreement for PI-RADS was suboptimal between trained and untrained radiologists (κ = 0.643), the scoring system showed stronger consensus (κ = 0.808).

CONCLUSION: This scoring system demonstrating comparable diagnostic performance to PI-RADS and improving PPV, highlighting its potential clinical practicability.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Yang L, Ding Z, Wang X, et al. A comprehensive scoring system integrating clinical and radiological variables for the detection of clinically significant prostate cancer on bi-parameter MRI: multi-center comparison with multi-parametric MRI. Abdom Radiol (NY). 2025. PMID: 40536539. doi:10.1007/s00261-025-05075-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。